DrugPatentWatch Database Preview
Glaxo Grp Ltd Company Profile
What is the competitive landscape for GLAXO GRP LTD, and what generic alternatives to GLAXO GRP LTD drugs are available?
There are thirty US patents protecting GLAXO GRP LTD drugs.
There are five hundred and seventy-four patent family members on GLAXO GRP LTD drugs in fifty-two countries and twenty-six supplementary protection certificates in fourteen countries.
Summary for Glaxo Grp Ltd
| International Patents: | 574 |
| US Patents: | 30 |
| Tradenames: | 13 |
| Ingredients: | 4 |
| NDAs: | 8 |
Drugs and US Patents for Glaxo Grp Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | AA | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | RX | Yes | Yes | 6,161,724*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | RX | Yes | Yes | 7,832,351*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-001 | Jun 8, 2006 | RX | Yes | Yes | 7,143,908*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Glaxo Grp Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ADVAIR DISKUS 250/50 | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 021077-002 | Aug 24, 2000 | 7,225,808*PED | ➤ Sign Up |
| Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED;INHALATION | 021254-002 | Jun 8, 2006 | 5,270,305 | ➤ Sign Up |
| Glaxo Grp Ltd | ADVAIR DISKUS 250/50 | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 021077-002 | Aug 24, 2000 | 5,873,360*PED | ➤ Sign Up |
| Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | 5,068,249*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXO GRP LTD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2007-10-30 |
Non-Orange Book US Patents for Glaxo Grp Ltd
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,531,528 | Formulation containing anti-inflammatory androstane derivatives | ➤ Sign Up |
| 6,750,210 | Formulation containing novel anti-inflammatory androstane derivative | ➤ Sign Up |
| 8,505,773 | Indicating device | ➤ Sign Up |
| 7,073,768 | Device and method for setting a frame | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Glaxo Grp Ltd Drugs
Supplementary Protection Certificates for Glaxo Grp Ltd Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014 00021 | Denmark | ➤ Sign Up | PRODUCT NAME: VILANTEROL ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER VILANTEROL TRIFENATAT; REG. NO/DATE: EU/1/13/886/001-006 20131113 |
| 269 | Luxembourg | ➤ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
| C0014 | France | ➤ Sign Up | PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111 |
| 2014019 | Lithuania | ➤ Sign Up | PRODUCT NAME: VILANTEROLUM; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
